Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Study of the Disease Process of Lymphangioleiomyomatosis

NCT: NCT00001465 · RECRUITING

NCT IDNCT00001465
StatusRECRUITING
Start Date1995-12-18

Brief Summary

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.

Frequently Asked Questions

What is Study of the Disease Process of Lymphangioleiomyomatosis?

Study of the Disease Process of Lymphangioleiomyomatosis is a clinical trial registered under NCT00001465. Current status: RECRUITING.

What is the status of NCT00001465?

The current status of NCT00001465 (Study of the Disease Process of Lymphangioleiomyomatosis) is: RECRUITING.

When did Study of the Disease Process of Lymphangioleiomyomatosis start?

Study of the Disease Process of Lymphangioleiomyomatosis started on 1995-12-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.